Pancreatic Cancer Research

ResearcherHumanitas UniversityActive in the last 2 years

Francesca Gavazzi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3207-0292; OpenAlex author ID A5040724230. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. Metabolomic profiling of pancreatic juice: a potential prognostic tool for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.suronc.2026.102456↗
  2. Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol30040282↗
  3. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival. Co-author DOI 10.1016/j.dld.2021.06.006↗
  4. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2022.05.006↗
  5. Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreati… Co-author DOI 10.3390/cancers14112653↗
  6. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. Co-author DOI 10.1200/cci.21.00001↗
  7. Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells. Co-author DOI 10.1158/2326-6066.cir-19-0403↗
  8. Evaluation of the MDACC clinical classification system for pancreatic cancer patients in an European multicenter cohort. Co-author DOI 10.1016/j.ejso.2018.12.012↗
  9. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2015.1085147↗
  10. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Co-author DOI 10.1136/gutjnl-2015-309193↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alessandro Zerbi · 10 shared papers, 2016–2026 · strength 1.22
  2. Giovanni Luigi Capretti · 8 shared papers, 2016–2026 · strength 1.05
  3. Gennaro Nappo · 5 shared papers, 2020–2026 · strength 0.83
  4. Federica Marchesi · 5 shared papers, 2016–2026 · strength 0.58
  5. Marialuisa Barbagallo · 3 shared papers, 2020–2026 · strength 0.48
  6. Silvia Bozzarelli · 3 shared papers, 2022–2023 · strength 0.47
  7. Paola Allavena · 4 shared papers, 2016–2022 · strength 0.30
  8. Silvia Carrara · 2 shared papers, 2022 · strength 0.30
  9. Elena Desiato · 1 shared paper, 2026 · strength 0.28
  10. Greta Donisi · 2 shared papers, 2020–2023 · strength 0.26
  11. Giovanni Francesco Castino · 3 shared papers, 2016–2020 · strength 0.18
  12. Nina Cortese · 3 shared papers, 2016–2020 · strength 0.18
  13. Paola Cappello · 2 shared papers, 2016–2020 · strength 0.13
  14. Francesco Novelli · 2 shared papers, 2016–2020 · strength 0.13
  15. Mohammad Azhar Kamal · 1 shared paper, 2022 · strength 0.12
  16. Giuseppe Di Caro · 2 shared papers, 2016 · strength 0.10
  17. Katharina Beyer · 1 shared paper, 2021 · strength 0.09
  18. Jin Peng He · 1 shared paper, 2021 · strength 0.09
  19. Alessandra Pulvirenti · 1 shared paper, 2021 · strength 0.09
  20. Dimitris Bertsimas Ioannis · 1 shared paper, 2021 · strength 0.09
  21. Hideo Baba · 1 shared paper, 2021 · strength 0.09
  22. Michael Ian D'Angelica · 1 shared paper, 2021 · strength 0.09
  23. Carsten Kamphues · 1 shared paper, 2021 · strength 0.09
  24. Hendrik Seeliger · 1 shared paper, 2021 · strength 0.09
  25. Jacob L. van Dam · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.